All right. Thanks very much, everybody. Happy to be moderating this chat here with the Immunic management team. With me is Erik Lundgren and Jason Tardio. These guys have a somewhat important clinical readout coming up, maybe. We will see. But yeah, with that, just to be more serious, maybe I will have you two guys each just, if you want to say any prepared remarks around the setup for the company going into the end of the year with these two RMS readouts, and then we can dig more into vidofludimus calcium.
Absolutely. Thanks for having us. Thanks for your interest. I am Erik Lundgren, the CEO of Immunic. As Paul indicated, we have a couple very exciting weeks ahead of us. We have two phase III pivotal trials reading out in relapsing MS, the ENSURE-1 and ENSURE-2 studies. Those will be reading out in December, and they would be, assuming they are positive, they would be NDA filing-enabling. We are very focused on that. In addition, we are initiating a third phase III study. This one would be in progressive MS. That is called the ProTEct-MS study, getting that off the ground as well. So, we are looking at some very exciting near-term catalysts, preparing for NDA filing, and doing the commercial build to get ready.
Great. Yeah. Well, okay, maybe we will get right into it. You have these two RMS readouts coming up. Maybe just talk about the setup there. You got these two studies. What are you guys going to disclose in the top line, and what sort of target product profile are you hoping to reaffirm?
Yeah. I would start with what do we see as the big unmet needs in MS, and I think there are many, but I would draw your attention to two. The first one is really around progression. There has been a ton of innovation in MS over the last 20 years or so, but progression remains a very, very difficult place to move the needle on, and really the overwhelming unmet need. We think with our lead asset, which is called vidofludimus calcium, it would be the first approvable MS treatment that is neuroprotective in nature. It has two mechanisms. One is on the neuroinflammatory side, and one is on the neurodegenerative side. We think we have got a really interesting and unique shot at moving the needle in ways that other MS therapies have been unable to do on progression. So that is sort of unmet need number one.
The second big unmet need is really around safety and tolerability. There's a lot of medicines approved. It's really hard for patients to stay on them. I think we have demonstrated, out of a pretty robust safety database to date, 3,500 patients, a very, very unique safety and tolerability profile. That's going to matter right away, because there's a lot of need for medicines that people can start and stay on. In particular, there's a large bolus of patients, actively treated MS patients, that are on anti-CD20s today. Anti-CD20s are the dominant sort of class of treatment in relapsing MS, and they're really wonderful medicines, but you can't ablate people's B cells in perpetuity.
You need medicines that folks can come off of anti-CD20s and step onto and still confer disease control, hopefully do something on progression, and do so with a safety and tolerability profile that is consummate to the sort of challenge of treating people who are immunosuppressed.
Right. Okay. That's the thesis there, and then as it relates to this phase III study, maybe talk about the phase II data, and what does that data sort of predict for the most likely efficacy and safety profile to come out in pivotal trials?
Yeah. We ran a pretty robust phase II study in relapsing MS called the EMPhASIS study. It gave us three things that gave us a lot of confidence going into this. The first is looking at the MRI outcomes. Gadolinium-enhancing lesions are incredibly strong predictors in the phase II setting of the clinical outcomes in a phase III setting, and we had a very robust 78% reduction in Gadolinium-enhancing lesions in the phase II study. That gives us a tremendous amount of confidence that we not only have an active medicine here, but that it's clinically relevant range for the primary outcome in the phase IIIs. Second is, although they weren't powered, a phase II study wasn't powered for statistical significance on relapses. We did, of course, look at relapses, and we saw a 42% risk reduction in relapse, was the point estimate.
Not significant, obviously, again, but that's a really healthy place to be landing in terms of a read-through on the confidence. Then third is the safety and tolerability, and I'll keep coming back to that because I think it's so meaningful, but the safety and tolerability profile was I've looked at everything in MS for the last dozen years. I've never seen anything quite like this in terms of the safety and tolerability, and I think it's really highly differentiated. It addresses a lot of the limitations of the currently available therapies, and it's going to be pretty appealing to physicians and to patients.
Yep. Okay, great. You also talked at the start about disability progression being a significant unmet need, or maybe progression in general. But to that point, what is your expectation and thesis there around some of the secondary endpoints? Maybe you could also talk about the Nurr1 angle, and whether or not that angle is likely to manifest in the RMS data.
Yeah. With RMS studies, I think what's typically done, and we'll do the same, is because the event rate is, you're powering on relapses, and the event rate for progression is less common. So we're going to have these twin studies, same study protocols, so we will look at the progression endpoints in a pooled fashion. So that's a way to get a little bit more signal. But what I would expect, Paul, is I would expect a numerical advantage. I would expect to see consistency across, but I do think in an 18-month relapsing study, the biostats are kind of against a screaming P-value, but we'll see. I mean, we're going to give ourselves the absolute best shot at seeing it. We certainly hope to see it, and if we don't see it, I think it wouldn't cause me to erode my confidence in Nurr1.
I think this is a study that's built to look at relapses and MRI and safety. It's certainly not a set of studies built to look at progression. That's why we're going to run a third study that is built around progression in a progressing population with progression endpoints and powered to do it.
What would you define as a home run safety tolerability profile in phase III?
Well, I think I'd look first to, are we able to address the main problems that are out there among what we hear from patients? You want a clean liver signal, so that's one. You want to address infection imbalances, in particular, serious or opportunistic infection imbalances. That would be number two. Then I think you want to look at the day-to-day tolerability issues that are the number one driver of treatment discontinuation amongst the oral treatments that are currently approved in MS. This is nausea, vomiting, diarrhea, flushing, these types of symptoms. So you want to make sure that you're handling those. Then there's another medicine that was approved about 15 years ago called teriflunomide or AUBAGIO, which is a DHODH inhibitor, which we share that targeting mechanistic pathway with. They also have alopecia rates, like, north of 20%.
That's not a fantastic thing to have in a population of people who are two-thirds female, diagnosed around 30 years of age. So, we want to be able to clean up some of those issues as well.
Okay.
We expect to see that based on our phase II data.
Okay, got it. Anything to add, Jason?
No, I think Erik tackled it quite well. I think the thing to remember, again, is all the available oral disease-modifying therapies today come with these Achilles heels. They have a trade-off on the safety side of things, again, for hepatotox, increased risk of malignancies, increased risk of serious infections like PML. They also have these acute adverse events that make it very, very difficult for these patients to stay on these therapies. Again, when clinicians and patients alike think about a disease-modifying therapy in MS, it's around the totality of the attributes. Our belief is that we're going to deliver a highly differentiated oral disease-modifying therapy that can potentially deliver the best in oral class benefit-risk profile. That's versus the currently marketed products and any future products, like BTK inhibitors or others, that might be coming to the market.
On that point, Jason, when we think about I know your primary endpoint is time to first relapse, but it seems simpler to compare these drugs on ARR, and tell me if you agree or not. Do you think it's going to be a fair comparison to look at the ARR in this phase III program and compare it to the older AUBAGIO, Tecfidera, Gilenya data? Maybe that's one question. Also, how would you compare it to the remibrutinib data, given that study has an active control?
Yeah, we should never cross-compare data, first and foremost.
Do you think physicians will, though?
Everyone does, but we should never because, think about these studies that were done
If we don't cross-compare data, then I don't have a job.
We want you to be gainfully employed. All right, so let's assume we do. In seriousness here, the patient populations from 20 plus, 25, even 15 years ago, are so different than the patient populations we're treating today. The relapse rates over time have gone down considerably, as Erik has alluded to. Confirmed disability events have gone down considerably because we're identifying patients younger. These are healthier patients that are getting into trials. It is extremely difficult to try and cross-compare. But what I would tell you, collectively speaking, as Erik alluded to, we expect to see relapse reduction on time to first relapse in the 30% range, give or take. If we deliver that with good MRI data, with the safety and tolerability profile that we've seen to date, we think we have a highly competitive and marketed product.
In those ranges of relapse reduction, we will be highly competitive against these oral products that you just mentioned, the fumarates of the world, the S1P modulators, et cetera. I go back to the fact that it is not just numerical reduction on efficacy that drives prescription behavior in this category. In fact, when you poll clinicians, when you poll patients, what you find is that safety and tolerability is equally important, if not, in many instances, more important than the overall efficacy profile of a medicine. Because this is a chronic disease. These patients are going to be on these medicines for prolonged periods of time. Of course, like with any medicine, if they cannot take the medicine because it is intolerable, then they are never going to benefit from the medicine itself. It is a holistic picture.
Again, we believe vidofludimus calcium is going to offer a highly differentiated holistic picture.
Yeah. Okay. On the commercial side, can you talk about who you think are the likely early or just over time adopters of vidofludimus calcium, and how would you size each of those populations into market opportunities?
Yeah, so we look at the market, and we have identified what we think are three very large and underserved patient populations today. The first, and probably the lowest hanging fruit, as we would say, are just patients who prefer oral disease-modifying therapies. This remains a sizable percentage of the market. It is about 25%-30% of all prescriptions today are for oral disease-modifying therapies. We have talked about the limitations of the currently marketed products. We believe we will compete quite heavily for a large market share within these patients that just prefer that modality. The second patient segment are patients sequencing off of the anti-CD20 class of medicines. These medicines have transformed the care of MS, specifically on relapsing disease. They own about a 50% share of the market. What is quite clear today is that you cannot keep someone on a broad B-cell depleting therapy forever.
What we know is about 10% of patients on an anti-CD20 today is actively looking to discontinue that medicine on an annual basis. Another 15% of patients on a CD20 today are using extended interval dosing to minimize the safety risks associated with that class. Collectively speaking, that represents 25% of patients on a CD20, or 40,000 patients that are actively going to be looking to sequence away from that class of medicines. We think vidofludimus calcium, given that it's an immunomodulator, given its safety profile, given its antiviral properties, would be a great medicine to switch, especially patients that are having infections on that class of medicines. Even those patients that are switching because of progression independent of relapse activity, we believe the Nurr1 story, the neuroprotective story, or potential impact on neurodegeneration would offer a very, very nice solution.
The third segment are just older individuals living with relapsing disease. The innovation over these last 30 years in this space has changed the demographic of what a relapsing patient looks like today. Based on claims analysis, we believe that it's about 40%-50% of all individuals with a diagnosis of relapsing MS today in the U.S. are aged 55 or older. Why is this important? There's unique treatment considerations for these older patient populations. Immunosenescence begins to kick in, so the body's ability to fight infection just wanes with age. These patients have comorbidities, they're on polypharmacy, so again, you can't have this population on potent immunosuppressant-like therapies. We believe vidofludimus, given the profile that we've discussed, will be a very, very smart and powerful medicine for, again, this population.
Yeah, the key thing just for people to understand, I think, is that this is a very heterogeneous patient population, and people's needs change over the course of their therapy. What you need when you're first diagnosed and you're young and your immune system might be really revved up is going to be a little bit different than when you're 55 years old or 52 years old and you've kind of gotten your relapses under control for a bit. I think this is not a sort of one class takes the whole kind of pie type of a situation. What's true in MS is that novel mechanisms of action are valued. We're coming with the first potentially neuroprotective agent ever to be approved in this class, and we think there's going to be a lot of interest in that.
Yeah. Okay. Makes sense. How do you guys think about building a business here commercially? Maybe talk about the target call point with physicians, how many reps you need, and sort of like, you have experience doing this, both of you, at bigger companies. Is this a market that a small emerging biotech can compete in well?
I think the answer to that is without a doubt. I think there's a very good recent analog in TG Therapeutics to show that a small, relatively kind of first-time launching company can step into the space and compete quite well. I think a couple of things to remember here. First of all, there's really three active companies competing in the space, right? You have Novartis, you have Roche, and you have TG Therapeutics, right? I think the space is ripe for another manufacturer like Immunic to step into the space. The other thing to remember is that there's roughly 3,000 clinicians writing 80% of the volume of prescriptions. So you can be very hyper-targeted on where you're going. We've talked a little bit about the growth segments of the patient populations that we would focus on.
You could further segment the market based upon some of these unique populations that these clinicians might be treating. The approach that we plan to take is a targeted approach. We plan, back 20 years ago, Paul, you would have had to hire 200- 300 reps to try and compete in the space. That is clearly not the case today. We're not going to, for competitive purposes, talk specifically on the numbers we think, but it's much lower than that. We will have other customer-facing roles that will support the patient and clinician journey in prescribing these medicines, like MSLs, TLLs, field reimbursement managers, et cetera. I think the last point I'd make is that, as you've mentioned, I come from a background in marketing many of these products. Erik came to us from Genentech.
We know this space, we know the top talent in this space, and our expectation is we're going to go hire the best of the best to join the company and to really help us market and commercialize this product.
Yep. Okay, great. Yeah, maybe just one more question on remibrutinib since it comes up so much. I mean, some of the patient segments that you've talked about, Jason, are segments strategically that I'm sure that drug will be positioned in. Like, how do you guys expect physicians to make a choice on what is the right option for a CD20 switch or for an older patient or things like that?
I can take the first shot at it. I mean, I would say first of all, there is plenty of room in the market for vidofludimus calcium and remibrutinib to compete and thrive. I think remibrutinib will be a successful medicine. I also am very confident vidofludimus calcium will be a successful medicine. Some places where I think we might end up seeing some advantage, as a reminder, we have not unlocked our data yet to take a look at it. So obviously, reserve the right to sort of come back to this question once we have seen what we have. But I think they showed up with a relatively clean liver profile. I think that was a big question that the field was curious about, and they deserve credit for that. But they do have a nearly 2-to-1 imbalance on serious infection risk.
They had a pretty strong imbalance on bleeding risks. They have a kind of a complicated DDI sort of profile to sort of navigate. And if you think about the patient I just keep thinking about is the one that Jason painted a picture of. So I have been on an anti-CD20 for, let us say, five years. I have depleted my B cells. I have gotten my relapses under control. I have not had a blip on my MRI in a couple years, but I am worried about serious infection risk down the line. Am I going to reach for a BTKI, which is still impacting B cells, not depleting them, but still sort of affecting B cells? It has a serious infection imbalance, has some other hangover kind of questions in the class. Maybe I am an older patient, I have got some polypharmacy considerations.
I just do not think that Remi is going to be the first thing that the patient or the physician reach for in that particular patient. There are others for whom they might. But my point is, I think we can both succeed. And frankly, my expectation is that over the 40-year journey that someone is being treated with DMTs in MS, they will probably end up seeing remibrutinib, and they will probably end up seeing vidofludimus calcium along the way.
Right.
That is just where it is.
Yep. Okay. With there being generics in this market now, what do you guys think the most likely step edits are to prescribing vidofludimus calcium when approved?
Yeah. There's very good recent analogs around how branded products are treated in this space. In the oral class, for example, just a couple things from an access perspective, there's still very high WAC pricing here, right? The average oral disease-modifying therapy in MS is priced today at about $115,000 USD. The gross to net on average is anywhere in the 30% range, so there's high net per patient pricing here. All the branded products are treated the same. They're placed on a specialty category. They have to be prescribed by a specialist. There's usually a prior authorization, usually just to confirm the diagnosis of the disease. And then most plans require a failure of one or two previous therapies. They aren't prescriptive enough to sit here and say, "You must step through this product A to get to product B.
Like, you don't think they'll say generic AUBAGIO? That's always the-
That's the question we always get. Remember, our medicine is vastly different. We share one of the mechanisms of this product is a DHODH inhibitor, but we do it in a much more selective manner.
Right.
The data to date supports a much cleaner and safer profile versus that. Our medicine is a Nurr1 activator, of which we know AUBAGIO or teriflunomide does not bind to nor activate that target. The chemistry is completely different. The PK/PD profile is completely different. I think you are going to be hard-pressed to find a PBM or a payer plan that is going to say, "You must fail on this generic product, teriflunomide, to get to vidofludimus calcium." Again, the other thing I will just make mention here is that, two points, is that the branded products in the space today have large coverage. It is over 90% coverage across the plans. Even in the categories in which there is generic products on the market, it is about a 50/50 split of use of branded products versus generics.
It is not like the generics make up 90% of a specific class of medicines, et cetera. Again, we believe that we will be able to sell through and pull through. I think that there is wind at our back here, Paul.
Makes sense. Do you want to talk a little bit about progressive MS, the data there, and the planned phase III?
Yeah, I would love to. We had an R&D day last week. We were able to sort of roll out some of the specifics around what we are calling the ProTEct-MS study, which is a phase III study in progressive MS. We are initiating it now, first patient in expected first half of next year. This is a study of around 1,400 patients. We will be using a progression endpoint, which is time to worsening or a nine-Hole Peg Test to power it. Yeah, we think this is extraordinarily exciting. It is on thesis for Nurr1. We are really leaning into this opportunity on the basis of a phase II study that we have conducted called the CALLIPER study, which was a large phase II study, 467 patients. What we saw in that study were a couple things that were really interesting.
I should, in transparency, note that the primary endpoint was whole brain atrophy, and it actually missed on whole brain atrophy. This is a phase II study. The reason whole brain atrophy was selected is there's not really a good phase II marker that's predictive of phase III success. At the time the study was initiated, people thought maybe whole brain atrophy would be a good marker. It has been subsequently shown in meta-analyses to have really no correlation whatsoever with progression, which is unfortunate for the company that that was the primary endpoint of the study. You don't throw the baby out with the bathwater, because what we saw beyond the primary was a couple things that were really interesting, including on imaging.
In terms of volume, we looked at sort of sub-regions of the brain that are much more sensitive, so thalamic volume, massive advantage to active treatment. You saw in slowly expanding lesions, which is thought to be a really emerging biomarker that's looking at the smoldering disease. We saw statistical significant impact on SELs. Then clinically, we looked at, it's not powered for clinical outcomes, but we saw an impact on worsening, and we also saw an impact on improvement, so people actually improving on the medicine. Last thing I'll say on this is we did a subgroup analysis, a large subgroup though, it was like about 85% of the patients, that were not only non-relapsing but also non-active, meaning at their baseline screening visit, they had no Gd-enhancing lesions. So, no evidence that there's an inflammatory process that's going on.
In that population, we saw not only the benefits that we were looking at on progression holding, they actually looked stronger in that sub-cohort of patients. This is hugely meaningful because if you look at something like ocrelizumab, which has a label in primary progressive, their original data was largely driven by the opposite cohort, which was a younger gad lesion kind of based population. The group that no one's been able to really move the needle on is this truly non-active population, and we did. Now, it's a phase II study, so let's not get too over our skis, but it is aligned with a neuroprotective mechanism. And it's either noise that won't hold up in a larger trial, or it's some of the most compelling evidence we have of Nurr1 as a clinically meaningful target in progressive MS.
We're obviously betting on the latter, and we're going to chase that theory down to the ground with a big powered study to show it.
Great. Maybe in the last minute here, do you guys just want to wrap up and touch upon your cash runway into data?
Yeah, sure. We had a big financing event that happened earlier this year in February, that generated $200 million of proceeds for the company. We have been working through that. That allows us to get aggressive, read out of two phase III studies, plan for a third, and start the commercial build. There were some warrants that were a part of that, so there is a tranche two of warrants that have the opportunity to convert on positive ENSURE-1 and ENSURE-2 data, so coming up right around the corner. Should that all convert, that is another $200 million. If that converts, that gives us a runway into mid-2028. So, I would say we are in a pretty comfortable position on the balance sheet. Data and market supporting, we will be looking at different financing options on the back of data as well to strengthen it further.
Yeah. Great. Best of luck, guys. Always great to see you.
All right.
Thank you.
Thanks, Paul.
Thanks.